How much revenue did Affimed generate this year?
Affimed has achieved a revenue of 5.36 M EUR this year.
Affimed Revenue 2024
Affimed Revenue
5.36 M EUR
Affimed Dividend yield
Ticker
AFMD
ISIN
NL0010872420
WKN
A12BHU
In 2024, Affimed's sales reached 5.36 M EUR, a -35.26% difference from the 8.28 M EUR sales recorded in the previous year.
The Affimed Revenue history
| YEAR | REVENUE (undefined EUR) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 238.62 | 2,90 |
| 2028e | 115.29 | 6,01 |
| 2027e | 41.19 | 16,82 |
| 2026e | 17.65 | 39,25 |
| 2025e | 6.24 | 110,92 |
| 2024e | 5.36 | 129,29 |
| 2023 | 8.28 | 83,70 |
| 2022 | 41.35 | 94,85 |
| 2021 | 40.37 | 94,65 |
| 2020 | 28.36 | 93,90 |
| 2019 | 21.39 | 92,75 |
| 2018 | 23.74 | 95,20 |
| 2017 | 2.01 | 50,75 |
| 2016 | 6.31 | 83,84 |
| 2015 | 7.56 | 88,10 |
| 2014 | 3.38 | 75,15 |
| 2013 | 5.09 | 86,05 |
| 2012 | 1.17 | 52,99 |
Affimed Aktienanalyse
What does Affimed do?
Affimed NV is a company specializing in the research, development, and marketing of immunotherapies for various types of cancer. The company was founded in 2000 and is headquartered in Heidelberg, Germany. It has been listed on the NASDAQ since 2014. Affimed focuses on developing innovative immunotherapies that adapt the body's immune defense mechanisms. The goal is to stimulate the body's defense against cancer cells. The company divides its work into three areas, reflected in its product range: 1. NK cell engager platform (NKG2D and CD16A engagers) 2. T cell engager platform (tandem fusions and bi- and tri-specifics) 3. ACCEL platform® (antibody-cell conjugates, enhanced loading) Affimed specializes in developing medicines for specific types of cancer with high medical needs, such as certain forms of lymphomas and solid tumors. The company collaborates with other companies to jointly develop and market medications. Its business model is based on partnerships to finance the development and commercialization of medications. In summary, Affimed NV specializes in the development of targeted immunotherapies for combating cancer cells. Its products specifically target NK cells and T cells and aim to promote an effective immune response against certain types of cancer. The company collaborates with other companies to advance therapy development and bring them to market. Affimed NV specializes in the development of immunotherapies for targeted treatment of cancer cells. Affimed ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Affimed's Sales Figures
The sales figures of Affimed originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Affimed’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Affimed's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Affimed’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Affimed Stock
How much was the turnover of the company Affimed compared to the previous year?
The revenue of Affimed has increased by -35.26% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Affimed?
The revenue of Affimed is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Affimed measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Affimed so important for investors?
The revenue of Affimed is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Affimed pay?
Over the past 12 months, Affimed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Affimed is expected to pay a dividend of 0 EUR.
What is the dividend yield of Affimed?
The current dividend yield of Affimed is .
When does Affimed pay dividends?
Affimed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Affimed?
Affimed paid dividends every year for the past 0 years.
What is the dividend of Affimed?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Affimed located?
Affimed is assigned to the 'Health' sector.
Wann musste ich die Aktien von Affimed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Affimed from 5/21/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/21/2024.
When did Affimed pay the last dividend?
The last dividend was paid out on 5/21/2024.
What was the dividend of Affimed in the year 2023?
In the year 2023, Affimed distributed 0 EUR as dividends.
In which currency does Affimed pay out the dividend?
The dividends of Affimed are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Affimed stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Affimed
Our stock analysis for Affimed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Affimed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
